- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-1-1-3-3-3-3-mer
- Ligands
- 8 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.2: 9 residues within 4Å:- Chain I: E.204, P.205, V.247, L.254, N.255, N.369, V.437, S.438
- Ligands: NAG.20
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:V.437
NAG-NAG-BMA.5: 11 residues within 4Å:- Chain K: E.204, P.205, V.247, L.254, N.255, N.369, G.371, C.436, V.437, S.438
- Ligands: NAG-NAG.6
2 PLIP interactions:2 interactions with chain K- Hydrogen bonds: K:G.371, K:V.437
NAG-NAG-BMA.10: 11 residues within 4Å:- Chain M: E.204, P.205, V.247, L.254, N.255, N.369, G.371, C.436, V.437, S.438
- Ligands: NAG.56
2 PLIP interactions:2 interactions with chain M- Hydrogen bonds: M:G.371, M:V.437
- 49 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.12: 3 residues within 4Å:- Chain I: E.88, N.89
- Chain J: S.17
Ligand excluded by PLIPNAG.13: 1 residues within 4Å:- Chain I: N.134
Ligand excluded by PLIPNAG.14: 7 residues within 4Å:- Chain I: V.135, T.136, N.137, N.149, Y.166, L.168, D.313
Ligand excluded by PLIPNAG.15: 4 residues within 4Å:- Chain A: G.56, D.58
- Chain I: N.153, R.162
Ligand excluded by PLIPNAG.16: 4 residues within 4Å:- Chain I: R.185, N.190, T.191
- Chain K: R.301
Ligand excluded by PLIPNAG.17: 5 residues within 4Å:- Chain I: N.227, T.229, S.267, I.270, H.344
Ligand excluded by PLIPNAG.18: 2 residues within 4Å:- Chain I: N.269, T.271
Ligand excluded by PLIPNAG.19: 4 residues within 4Å:- Chain I: Q.286, N.288, S.326, V.437
Ligand excluded by PLIPNAG.20: 3 residues within 4Å:- Chain I: N.255, N.439
- Ligands: NAG-NAG-BMA.2
Ligand excluded by PLIPNAG.21: 6 residues within 4Å:- Chain I: E.260, E.261, E.262, N.282, T.283, K.336
Ligand excluded by PLIPNAG.22: 2 residues within 4Å:- Chain I: K.222, N.234
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain I: N.294, I.315, V.433
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain J: N.100
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain J: N.107, S.109, E.110
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain J: K.122, N.126
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain K: E.88, N.89
- Chain L: S.17
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain K: N.134, K.148
Ligand excluded by PLIPNAG.29: 1 residues within 4Å:- Chain K: N.138
Ligand excluded by PLIPNAG.30: 6 residues within 4Å:- Chain K: V.135, T.136, N.149, Y.166, L.168, D.313
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain K: R.185, N.190, T.191
- Chain M: R.301
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain K: N.227, T.229, S.267
Ligand excluded by PLIPNAG.33: 1 residues within 4Å:- Chain K: N.234
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain K: N.269, T.271, N.272
Ligand excluded by PLIPNAG.35: 5 residues within 4Å:- Chain K: E.260, E.261, N.282, T.283, K.336
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain K: Q.286, N.288, N.324, S.326
- Ligands: NAG.38
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain K: N.294, I.315, V.433
Ligand excluded by PLIPNAG.38: 5 residues within 4Å:- Chain K: T.290, H.322, N.324, R.435
- Ligands: NAG.36
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain K: N.347
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain K: S.380, N.384
- Ligands: NAG-NAG.7
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain L: N.100, S.102, I.130
Ligand excluded by PLIPNAG.42: 4 residues within 4Å:- Chain L: N.105, N.107, S.109, E.110
Ligand excluded by PLIPNAG.43: 1 residues within 4Å:- Chain L: N.126
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain L: T.18, N.114
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain M: E.88, N.89
- Chain N: G.13, S.17
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain M: R.185, N.190, T.191
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain M: N.227, T.229, S.267
Ligand excluded by PLIPNAG.48: 1 residues within 4Å:- Chain M: N.234
Ligand excluded by PLIPNAG.49: 3 residues within 4Å:- Chain M: N.269, T.271, N.272
Ligand excluded by PLIPNAG.50: 5 residues within 4Å:- Chain M: E.261, E.262, N.282, T.283, K.336
Ligand excluded by PLIPNAG.51: 7 residues within 4Å:- Chain M: Q.286, N.288, N.324, S.326, R.435, V.437
- Ligands: NAG.52
Ligand excluded by PLIPNAG.52: 5 residues within 4Å:- Chain M: T.290, H.322, N.324, R.435
- Ligands: NAG.51
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain M: N.294, I.315, V.433
Ligand excluded by PLIPNAG.54: 3 residues within 4Å:- Chain M: N.331, E.332, W.387
Ligand excluded by PLIPNAG.55: 2 residues within 4Å:- Chain M: S.380, N.384
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain M: S.284, N.439
- Ligands: NAG-NAG-BMA.10
Ligand excluded by PLIPNAG.57: 2 residues within 4Å:- Chain N: N.100, S.102
Ligand excluded by PLIPNAG.58: 3 residues within 4Å:- Chain N: N.107, S.109, E.110
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain N: N.114, M.115, Q.119
Ligand excluded by PLIPNAG.60: 1 residues within 4Å:- Chain N: N.126
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ma, K.M. et al., HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates. Sci Immunol (2025)
- Release Date
- 2025-07-30
- Peptides
- RM038 fragment antigen binding heavy chain: A
RM038 fragment antigen binding light chain: B
RM20A3 fragment antigen binding light chain: CEH
RM20A3 fragment antigen binding heavy chain: DFG
Envelope glycoprotein gp160: IKM
Transmembrane protein gp41: JLN - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
HB
LC
GE
JH
ND
IF
KG
MI
AK
CM
DJ
BL
EN
F
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-1-1-3-3-3-3-mer
- Ligands
- 8 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 49 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ma, K.M. et al., HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates. Sci Immunol (2025)
- Release Date
- 2025-07-30
- Peptides
- RM038 fragment antigen binding heavy chain: A
RM038 fragment antigen binding light chain: B
RM20A3 fragment antigen binding light chain: CEH
RM20A3 fragment antigen binding heavy chain: DFG
Envelope glycoprotein gp160: IKM
Transmembrane protein gp41: JLN - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
HB
LC
GE
JH
ND
IF
KG
MI
AK
CM
DJ
BL
EN
F